首页> 外文期刊>European journal of pain : >Randomized double‐blind controlled study of bedtime low‐dose amitriptyline in chronic neck pain
【24h】

Randomized double‐blind controlled study of bedtime low‐dose amitriptyline in chronic neck pain

机译:随机双盲对照研究睡前低剂量氨基型慢性颈部疼痛

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Amitriptyline has well‐established efficacy in several chronic pain conditions. While optimal treatment for chronic neck pain (CNP) remains controversial, amitriptyline was not tested for CNP. We evaluated the effect of bedtime amitriptyline in the management of CNP. Methods A total of 220 patients suffering from idiopathic CNP were randomized to receive either placebo pill ( n ?=?108) or 5?mg of amitriptyline ( n ?=?112) at bedtime for 2?months. Primary outcome measure was visual analog scale (VAS) for pain. Secondary outcome measures were neck pain disability index (NPDI), Bergen Insomnia Score (BIS) and Hospital Anxiety and Depression Scale (HAD), measured before and at the end of 2?months of treatment, with the percentage of patient satisfaction measured at the end of follow‐up only. Results Eight of 112 patients (7.14%) in the amitriptyline group withdrew from the study because of intolerance. Amitriptyline group showed significantly lower VAS scores than placebo group (3.34?±?1.45 vs. 6.12?±?0.92; p ??0.0001), which corresponds to a 53.06?±?20.29% of improvement from baseline pain as compared to 14.41?±?11.05%, respectively ( p ??0.0001). Similar significant improvements were observed with lesser extents for secondary outcome measures: NPDI, BIS, HAD‐A, HAD‐D and percentage of patient satisfaction. Conclusion Low‐dose amitriptyline is effective for the management of idiopathic CNP with few side effects and high patients’ satisfaction. Significance This randomized controlled trial is the first to show the effectiveness and tolerance of a medication, low‐dose amitriptyline, in managing idiopathic chronic neck pain and its related comorbidities. The optimal treatment of this condition was still controversial in the literature. It extends the indication of low‐dose amitriptyline to another chronic pain condition.
机译:摘要背景Amitriptyline在几种慢性疼痛条件下具有良好的疗效。虽然对慢性颈部疼痛(CNP)的最佳治疗仍然存在争议,但没有对CNP进行测试。我们评估了睡前Amitiptyline在CNP管理中的影响。方法患有特发性CNP的220名患者随机分配,以在睡前接收安慰剂丸(n?= 108)或5μmmitiptyline(n?=α112)2个月。主要结果测量是视觉模拟量表(VAS)的疼痛。次要结果措施是颈部疼痛残疾指数(NPDI),卑尔根失眠评分(BIS)和医院焦虑和抑郁尺度(曾经),在2个月的治疗前和2个月之前测量,患者满意度百分比测量仅限后续结束。结果阿米替尔集团112名患者(7.14%)中八个因不耐受而退出该研究。 amitiptyline组显示出的VAS分数明显低于安慰剂组(3.34?±1.45与6.12?±0.92; p?&?0.0001),其对应于53.06?±20.29%,与基线疼痛相比分别为14.41?±11.05%(p≤≤0.0001)。对次要结果措施的较小范围观察到类似的显着改善:NPDI,BIS,HAD-A,HAT-D和患者满意度的百分比。结论低剂量阿米替尔对特发性CNP的管理有效,副作用和高患者满意度。意义这种随机对照试验是第一个显示药物,低剂量阿米替林,管理特发性慢性颈部疼痛及其相关合并症的有效性和耐受性。在文献中,这种情况的最佳治疗仍存在争议。它将低剂量氨基百分之一体的指示扩展到另一种慢性疼痛条件。

著录项

  • 来源
    《European journal of pain :》 |2018年第6期|共8页
  • 作者单位

    Laboratory of Research in NeurosciencesSaint‐Joseph UniversityBeirut Lebanon;

    Laboratory of Research in NeurosciencesSaint‐Joseph UniversityBeirut Lebanon;

    Laboratory of Research in NeurosciencesSaint‐Joseph UniversityBeirut Lebanon;

    Laboratory of Research in NeurosciencesSaint‐Joseph UniversityBeirut Lebanon;

    Lyon Neuroscience Research Center ‐ INSERM U1028 (Central Integration of Pain)UJM St‐EtienneFrance;

    Lyon Neuroscience Research Center ‐ INSERM U1028 (Central Integration of Pain)UCB Lyon 1France;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 诊断学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号